Last reviewed · How we verify
Adalimumab ID
Adalimumab ID is a TNF-alpha inhibitor Biologic drug developed by Centre for Human Drug Research, Netherlands. It is currently in Phase 1 development for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
Tumour necrosis factor-alpha inhibitor
Adalimumab ID is a microneedle delivery method for the treatment of pain and injection site conditions, compared to subcutaneous injection. Adalimumab ID is a TNF-alpha inhibitor, classified as an antibody inhibitor, targeting tumor necrosis factor.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adalimumab ID |
|---|---|
| Sponsor | Centre for Human Drug Research, Netherlands |
| Drug class | TNF-alpha inhibitor |
| Target | Tumour necrosis factor-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that binds to tumour necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Adalimumab Microneedles in Healthy Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab ID CI brief — competitive landscape report
- Adalimumab ID updates RSS · CI watch RSS
- Centre for Human Drug Research, Netherlands portfolio CI
Frequently asked questions about Adalimumab ID
What is Adalimumab ID?
How does Adalimumab ID work?
What is Adalimumab ID used for?
Who makes Adalimumab ID?
What drug class is Adalimumab ID in?
What development phase is Adalimumab ID in?
What are the side effects of Adalimumab ID?
What does Adalimumab ID target?
Related
- Drug class: All TNF-alpha inhibitor drugs
- Target: All drugs targeting Tumour necrosis factor-alpha
- Manufacturer: Centre for Human Drug Research, Netherlands — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Psoriatic arthritis
- Indication: Drugs for Ankylosing spondylitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing